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APPENDIX METHODS: 
 
Plasmids 
Flag-FBXW7alpha, Flag-FBXW7beta, Flag-FBXW7gamma, HA-Cullin1, flag-FBXW1, flag-Skp2, 
flag-FBXW4 plasmids were kind gifts of Markus Welcker and Bruce Clurman (Fred Hutchinson 
Cancer Research Center, Seattle, USA). Skp1 and myc-Cul1 plasmids were kind gifts of Nikita Popov 
(University Würzburg, Germany). STYX-pcDNA3, YFP2-STYX, HA-STYX were described before 
(Reiterer et al, 2013). MCL1 plasmid was obtained from Addgene (25375). STYX_FQQ was 
generated by replacing 76FQQ78 with alanine residues. Primers used for site directed mutagenesis  are 
the following: 
Forward: 5’- TGG ATT ATC TGC AAT ATC CAG GAC TAA ATA TCT AAA TAA CGC CGC 
AGC GTT TGG TTT AAT AAA GTT TGC TTC AAT ATT TTG TCG TAT G-3’   
Reverse: 5’-CAT ACG ACA AAA TAT TGA AGC AAA CTT TAT TAA ACC AAA CGC TGC 
GGC GTT ATT TAG ATA TTT AGT CCT GGA TAT TGC AGA TAA TCC A -3’. 
HA-FBXW7alpha was obtained by subcloning FBXW7 into HA-pCMV. HA-FBXW7 lacking the F-
Box was cloned by site directed mutagenesis using the following primers: 
Froward: 5’GTGATAGAACCCCAGTTTCAATGCAAAGAAGAGGGGA3’as  
Reverse: 5’-TCCCCTCTTCTTTGCATTGAAACTGGGGTTCTATCAC-3’  
HA-FBXW7_R465C mutant was cloned with site directed mutagenesis using the following primers: 
Forward: 5’ CAT GAA GAT GCA TAC AAC ACA CAG TGG AAG TAT GCC C 3’ 
Reverse: 5’GGG CAT ACT TCC ACT GTG TGT TGT ATG CAT CTT CAT G 3’. 
YFP1-FBXW7 was obtained by PCR subcloning FBXW7 into YFP1-pcDNA3 (Reiterer et al 2013). 
YFP1-FBXW7_lacking the F-box was obtained by site directed mutagenesis using the primers 
described above. GST-FboxFBXW7 was obtained by PCR subcloning the F-Box of FBXW7 into 
pGEX-4t-3 vetcor. 
 
Cycloheximide chase 
Cells were treated with 50ug/ml cycloheximide for the indicated time periods. Subsequently cells were 
lysed in buffer (50 mM Tris⋅HCl, pH 7.4, 10 mM EDTA, 100 mM NaCl, 0.1% SDS, and 1% NP-40) 
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supplemented with proteinase inhibitor (cOmplete Mini; Roche) and phosphatase inhibitor 
(PhosSTOP; Roche). 
 
 
Real time PCR 
Cells were harvested using the RNA extraction kit (RNeasy, Qiagen), according to manufacturer’s 
instructions. Concentration and purity of mRNA was determined using a Spectrophotometer (Nano 
drop™). 1 µg total RNA was reverse transcribed into cDNA using High Capacity cDNA kit (Applied 
Bioscience) according to manufacturer’s instruction. The following primers were used:  
GAPDH-forward: 5′-CGCTCTCTGCTCCTCCTGTT-3′ 
GAPDH-reverse: 5′-CCATGGTGTCTGAGCGATGT-3′  
c-Myc-forward: 5′-TTCTCTCCGTCCTCGGATTC-3′   
c-Myc-reverse: 5′-TCATCTTCTTGTTCCTCCTCAGA-3′ 
STYX: Hs_STYX_1_SG QuantiTect Primer Assay (Qiagen) were used. 
Real-time quantitative PCR was performed using FASR-SYBR Green master mix (Applied 
Biosystems) according to manufacturer’s instructions.  
 
Tissue samples, RNA extraction, Affymetrix GeneChip hybridization, and QPCR 
Tissue specimens, 12 non-pathologic breast samples and 61 primary breast cancers, were obtained by 
patients who underwent surgery at the European Institute of Oncology (Milan, Italy). Written 
informed consent for research use of biological samples was obtained from all patients, and the 
research project was approved by the Institutional Ethical Committees. Samples were immediately 
snap-frozen in liquid nitrogen and stored at -800 C. Briefly, total RNA was extracted from 10-20 serial 
sections (10 µm thick) of snap-frozen specimens using commercial homogenization (QIAshredder) 
and purification (RNeasy Mini Kit) reagents (Qiagen, Valencia, CA, USA). RNA was analyzed with 
the Agilent 2100 Bioanalyzer (Agilent Technologies). Total RNA (500 ng) was amplified using the 
T7-Polymerase-based double linear amplification protocol. cRNA probes (25 µg) were hybridized 
onto the Affymetrix (Santa Clara, CA, USA) HG-U133 ChipSet, according to Affymetrix technical 
protocols. CEL files were analyzed with the Affymetrix's proprietary MAS5 pre-processing algorithm, 
and the average intensity of each array was scaled to a predefined value (target intensity) of 500, in 
order to make arrays comparable. Probeset signal values for STYX and FBXW7 were extracted and 
data analysis was performed using JMP 10.0 statistical software (SAS Institute, Inc).  
 
For STYX and FBXW7 mRNA reverse transcription quantitative real-time PCR (RT-qPCR) analysis, 
250 ng of total RNA (RNA concentration measured using the NanoDrop® ND-1000 
Spectrophotometer) were reverse transcribed with random primers using the SuperScript® VILO™ 
cDNA Synthesis Kit (Thermo Fisher Scientific) and 5 ng of cDNA/reaction were analyzed by PCR. 
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Quantitative PCR was performed with hydrolysis probes (Thermo Fisher Scientific) using the 
SsoAdvanced Universal Probes Supermix (Bio-Rad Laboratories) in 10 µl of final volume in 384-well 
plates. PCR reaction was run in LightCycler (LC) 480 real-time PCR instruments (Roche) using the 
following thermal cycling conditions: 1 cycle at 95°C for 30 sec, 45 cycles at 95°C for 5 sec, and 60°C 
for 30 sec. 
TaqMan gene expression assays were as follows: Hs00377042_m1 (human STYX, RefSeq 
NM_001130701.1, exon boundary 2-3, assay location 115, amplicon length 68 bp), Hs00217794_m1 
(human FBXW7, RefSeq NM_001013415.1, exon boundary 3-4, assay location 548, amplicon length 
76 bp), Hs03929097_g1 (human GAPDH, RefSeq NM_001256799, exon boundary 8-8, assay location 
1250, amplicon length 58 bp), Hs99999908_m1 (human GUSB, RefSeq NM_000181, exon boundary 
11-12, assay location 1925, amplicon length 81 bp), Hs02800695_m1 (human HPRT1, RefSeq 
NM_000194.2, exon boundary 2-3, assay location 297, amplicon length 82 bp) and Hs00427621_m1 
(human TBP, RefSeq NM_001172085, exon boundary 3-4, assay location 666, amplicon length 65 
bp). 
For RPLP0 detection a custom assay (Forward primer: CCATTGAAATCCTGAGTGATGT; Reverse 
primer: CAAAGTGGGAGCCAGCGA; Probe:  GCAGCTGATCAAGACTGGAGA) was designed 
using the Primer Express Software V3.0 (Thermo Fisher Scientific). 
Each target was assayed in triplicate and average Cq values were calculated (the average was 
calculated from triplicate values when the standard deviation was <0.4, or from the best duplicate 
values when the standard deviation was ≥0.4). Data (average Cq) were normalized on the average Cq 
value of five endogenous reference genes (GAPDH, GUSB, HPRT1, TBP and RPLP0) for accurate 
sample normalization and to the average of normal samples using the comparative Cq (2-ΔΔCq) 
method. Statistical analysis was performed using JMP 10.0 statistical software (SAS Institute, Inc). 
Raw Data and statistical analysis for STYX and FBXW7 are presented in Table EV3. The complete 
Affymetrix dataset is available upon request. 
 
 
APPENDIX FIGURE LEGENDS 
 
Figure S1. A, HeLa cells were transfected with two different siRNAs against STYX obtained from 
Dharmacon (D) or from Qiagen (Q). After 72 h, cells were lysed and immunoblotted as indicated. B, 
HeLa cells were transfected with a non-targeting siRNA (Co) or with the two different siRNAs 
targeting STYX (D and Q as in panel A). After 72 h, cells were lysed followed by 
immunoprecipitation and immunoblotting of FBXW7. B, HeLa cells were transfected with plasmids 
encoding YFP-tagged or HA-tagged FBXW7. In addition cells, were co-transfected with increasing 
amounts of STYX. After 24 h, cells were lysed and subjected to immunoprecipitation against HA 
followed by immunoblotting against the indicated proteins.  
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 Figure S2. A, GST-tagged F-box of FBXW7 was expressed in and purified from E-coli. The purified 
protein was incubated with a lysate from cells expressing HA-tagged STYX followed by GST-
pulldown and immunoblotting as indicated. B, FRET assay in HeLa cells expressing YFP-tagged 
FBXW7 and CFP-tagged SKP1 alone (orange bar) or together with non-tagged STYX (grey bar). The 
blue bar represents FRET between CFP-tagged SKP1 and the YFP signal emanating from the 
complementation of Y1-tagged FBXW7 and Y2-tagged STYX. FRET was determined using the 
acceptor photobleaching method. C, HeLa cells were transfected with an empty vector or with 
plasmids encoding for HA-tagged STYX, FBXW7 or SKP1. Cells were lysed 24 h after transfection 
and subjected to anti-HA immunoprecipitation followed by immunoblotting as indicated. D, 
evaluation of the YFP-BiFC experiment from Figure 5A.  
 
Figure S3. A, MDA-MB-231 cells were transfected with a non-targeting siRNA (siCo) or with siRNA 
against STYX (siSTYX). After 72 h, cells were treated with DMSO or Doxorubicin (10 µM) for 48 h 
followed by lysis and immunoblotting as indicated. B, HeLa cells transfected with siRNA against 
STYX or with non-targeting control (Co) were treated with doxorubicin (10 µM) for 8 hours followed 
by lysis and immunoblotting as indicated. C, MDA-MB-231 cells were transfected with a non-
targeting siRNA (siControl) or with siRNA against STYX (siSTYX). After 72 h, cells were treated 
with DMSO or Doxorubicin (10 µM) for 48 h. Afterwards cells were stained with 6-
carboxyfluorescein diacetate to label live cells (green) and with annexin-V Cy3 (red) to label apoptotic 
cells. Representative images are shown on the left side and an evaluation of three experiments is 
shown on the right side. Scale bar= 75µm. D, MDA-MB-231 cells stably expressing a non-targeting 
shRNA or an shRNA against STYX were plated on poly-hema treated dishes to prevent attachment 
(10’000 cells per well in a 96 well plate). Cells were grown for 5 days and were passaged for 10 times 
through a 20µl pipette tip followed by fixation in 4% PFA and imaging. The number of colonies was 
determined and an evaluation of 4 experiments is shown on the right side of the panel. Scale bar = 
250µm. 
 
Figure S4. STYX does not modulate the survival of patients with PIK3CA or GOLGA2 alterations. 
Kaplan-Meier plot of the relapse-free survival of 1660 breast cancer patients generated through the 
kmplot database (http://kmplot.com/).  
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Appendix Table S1- List of antibodies used in this work. 
 
Antibody nr company used 
flag-M2  F1804 Sigma Aldrich IF 
FLAG® M2-Peroxidase (HRP) mouse 
monoclonal antibody  A8592 Sigma Aldrich WB 
Monoclonal Anti-HA−Peroxidase antibody 
produced in mouse H6533 Sigma Aldrich WB 
STYX custom made Thermo Scientific WB 
c-myc 5605 Cell Signalling WB 
cyclinE sc-247 Santa Cruz WB 
Mcl-1 sc-819 Santa Cruz WB 
Skp1 sc-7163 Santa Cruz WB 
Cullin 1 sc-12761 Santa Cruz WB 
actin   Abcam WB 
tubulin   kind gift of Karl Matter WB 
Caspase-3 9662 Cell Signalling WB 
GFP ab32146 Abcam IF 
GST sc-138 Santa Cruz WB 
GFP 11814460001 Roche IF 
Vinculin   Thermo Fisher WB 
FBxW7 A301-720A Bethyl WB 	
